期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 7, 期 1, 页码 7-8出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2009.173
关键词
-
类别
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据